Navigation Links
OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Demonstrates Excellent Safety and Clinical Outcomes in High-Risk Elderly Patients

SEOUL, South Korea, April 29 /PRNewswire/ -- OrbusNeich today announced that a subset analysis of patients over 70 years of age in the final 12-month clinical results of the global e-HEALING Registry confirmed that the company's Genous Bio-engineered R stent is safe and demonstrates excellent clinical outcomes in this high-risk patient group.

The data were presented by Dr. Andres Iniguez, M.D., of the Hospital Universitario de Vigo in Vigo, Spain, at the Angioplasty Summit Transcatheter Cardiovascular Therapeutics Conference Asia Pacific (TCTAP) 2010 in Seoul, South Korea.  

The subset analysis evaluated 1,567 patients with a mean age of 75 years old from the e-HEALING clinical study and found a composite hierarchical major adverse cardiac event (MACE) rate of 9.9 percent with no Q-wave myocardial infarction (MI) at 12 months. The target lesion revascularization (TLR) rate was 6.7 percent, and the rate of target vessel failure (TVF) was 10.4 percent at 12 months.  Per Academic Research Consortium (ARC) definition, the definite and probable subacute thrombosis (SAT) rate at 12 months was 0.9 percent, and the rate of late stent thrombosis (LST) was 0.3 percent.

Of the 1,063 male (67.8%) and 504 female (32.2%) patients, 39 percent had a prior acute myocardial infarction. Of the 2,169 lesions treated in the patient subset, 54.5 percent were type B2 or C. The study protocol recommends that patients receive one month of dual antiplatelet therapy post index procedure.

"Elderly patients represent an important segment of individuals undergoing PCI procedures," said Dr. Iniguez, the presenter of the study. "We are especially pleased to see excellent clinical outcomes in this high-risk patient subset for whom long-term dual antiplatelet therapy is not ideal.  Elderly patients often require medication and non-cardiac surgery that can interfere with the post PCI standard of care. The Genous Bio-engineered R stent compares favorably to most DES registries without necessitating long-term dual antiplatelet therapy."

Al Novak, OrbusNeich's chairman and CEO, added, "Elderly patients are a challenging subset that often displays several co-morbidities and frequently benefits from a shorter course of dual antiplatelet therapy. This study confirms that the Genous Bio-engineered R stent is both an effective and safe treatment alternative that can satisfy the special needs of these older patients."

e-HEALING is a multi-center, worldwide (outside of the United States) prospective clinical registry conducted in 31 countries at 144 clinical centers.

About Genous  

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that accelerates the natural healing process of the vessel wall after stent implantation. The technology consists of an antibody surface coating that captures EPCs circulating in the blood, which form a functional endothelial layer that provides protection against thrombosis and modulates restenosis.

OrbusNeich's Genous Bio-engineered R stent has been commercially available in over 60 countries since 2005.  The Genous stent has been proven as a safe, effective alternative to drug-eluting stents and is supported by data from more than 6,000 patients in clinical studies.  There is a growing body of evidence from multiple clinical studies that the Genous stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Bio-engineered R stent, as well as stents, balloons and guiding catheters marketed under the names of Blazer™, R stent, Scoreflex™, Sapphire™, Sapphire NC, and Lumina™. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan.  OrbusNeich, which has provided medical devices to physicians through its predecessor companies since 1979, supplies products today to interventional cardiologists in more than 60 countries. For more information, visit  

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Presented at ACC/i2 Summit Demonstrate Impressive Long Term Clinical Outcomes in Real World Patients Treated with OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
2. OrbusNeich Announces First Patient Enrolled in Randomized Clinical Trial of Genous(TM) Bio-engineered R stent(TM) in China
3. Clinical Data Presented at Asia PCR/Sing LIVE Demonstrate Benefits of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) in Challenging Patient Subsets
4. Data From Multiple Clinical Trials of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2009
5. Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents
6. Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
7. Data From Multiple Clinical Trials of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008
8. Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents
9. Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents
10. Data from Randomized Pilot Study, Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
11. Clinical Impact of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) is Subject of Symposium at 16th Annual Scientific Congress of Hong Kong College of Cardiology
Post Your Comments:
(Date:11/30/2015)... décembre 2015 MEDTEC Japon ... conférence d,Asie portant sur la conception ... manufacturière, se tiendra à ... 22 avril 2016. ... Photo - Logo ...
(Date:11/30/2015)... -- Nevro Corp. (NYSE: NVRO ), a global medical ... treatment of chronic pain, today announced that the Patent Trial ... Office (USPTO) has denied instituting an inter partes ... --> --> On ... two petitions challenging the validity of certain claims of the ...
(Date:11/30/2015)... 2015 Next week, December 2-3, BIOMEDevice ... ) co-located events covering the latest in Medtech innovation, ... will draw more than 3,000 design industry professionals to ... The events, combined show floor will host more than ... --> --> BIOMEDevice features suppliers ...
Breaking Medicine Technology:
(Date:11/30/2015)... , ... November 30, 2015 , ... ... only four states in the U.S. require dental technicians to be certified or ... dental industry, NADL created the “What’s In Your Mouth?” campaign to inform dentists ...
(Date:11/30/2015)... ... November 30, 2015 , ... MOSI recently added two ... along with Back to the Jurassic to their collection of interactive exhibits within the ... dynamic worlds that will allow guests to get closer than ever to a range ...
(Date:11/30/2015)... ... 2015 , ... In an effort to provide local families ... Christian Church of Flint, MI, hosted a family-oriented evening themed on “Candy Land”, ... candy dubbed “Candy Mountain”. , A Forever Recovery, a holistic treatment center for ...
(Date:11/30/2015)... ... November 30, 2015 , ... The presidential race normally deals with political issues ... it a national news story when Donald Trump makes disparaging remarks about Hillary Clinton’s ... more than anyone wants to admit when it comes to how people are viewed ...
(Date:11/30/2015)... ... November 30, 2015 , ... Rick Sommer, president of Intellitec ... Management of Information Systems course. Based in Wilmington Delaware, Intellitec Solutions is an ... before student in the Enterprise Resource Planning (ERP) Systems class. The course focuses ...
Breaking Medicine News(10 mins):